Doctors represent hurdle for Lundbeck once again
Lundbeck’s research & development boss, Anders Gersel Pedersen, is pleased with the label given by the FDA to the company’s new potential blockbuster, antidepressant Brintellix. But the success of the product depends on the efficiency of commercial partner Takeda’s marketing machinery.
by Benjamin Werner Christensen
Antidepressant Brintellix has been approved for the US market, and it should merely be a matter of time before billions starting rolling into the accounts of Lundbeck and Japanese partner Takeda. The biggest hurdle for the product is to convince doctors that the drug is as good as the two companies believe it to be, a notion that is backed by a number of clinical trials.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Here are Lundbeck’s best-performing drugs
For abonnenter
Lundbeck launches alcohol pill in Denmark
For abonnenter
Either Lundbeck or the EU Commission is lying
For abonnenter
.jpg&w=384&q=75)
